Targeting IL-17 and TH17 cells in chronic inflammation
The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abs against IL-17/IL-17RA are in clinical trials for other autoimmune conditions [55].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [55]
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Research works printed but not linked: 1
- Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Cited by
Items 101–200 of 1,000
The presence, function and regulation of IL‐17 and Th17 cells in periodontitis
Cheng, W., Hughes, F. J., & Taams, L. S. (2014) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12238 · Cited by 159
Clinical implications of shared genetics and pathogenesis in autoimmune diseases
Zhernakova, A., Withoff, S., & Wijmenga, C. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.161 · Cited by 158
Komai, T., Inoue, M., Okamura, T., Morita, K., Iwasaki, Y., Sumitomo, S., Shoda, H., Yamamoto, K., & Fujio, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01364 · Cited by 176
“Also, a combination of TGF-β plus IL-17, a pro-inflammatory cytokine produced by Th17 cells (36), did not have synergistic inhibitory effects in antibody production of B cells (Figure 2D).”
BackgroundYe, L., Jiang, B., Deng, J., Du, J., Xiong, W., Guan, Y., Wen, Z., Huang, K., & Huang, Z. W. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401810 · Cited by 154
“Moreover, IL-17–transgenic mice are prone to develop collagen-induced arthritis (CIA), whereas blocking of endogenous IL-17 with its receptor in CIA results in the suppression of arthritis and reduced joint destruction (4, 5).”
BackgroundInfluentialSieper, J., Braun, J., Kay, J., Badalamenti, S., Radin, A. R., Jiao, L., Fiore, S., Momtahen, T., Yancopoulos, G. D., Stahl, N., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204963 · Cited by 127
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
Lai, Y., & Dong, C. (2015) · International Immunology · doi:10.1093/intimm/dxv063 · Cited by 162
Lugade, A. A., Bogner, P. N., Thatcher, T. H., Sime, P. J., Phipps, R. P., & Thanavala, Y. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302584 · Cited by 152
“In this article, we show that chronic cigarette smoke exposure followed by chronic infection results in decreased levels of Th1 and Th2 cytokines and decreased T cell and B cell function, but an increased IL-17 response; IL-17 is associated with maintenance of chronic inflammation (37, 38).”
BackgroundTestosterone Decreases House Dust Mite–Induced Type 2 and IL-17A–Mediated Airway Inflammation
Fuseini, H., Yung, J. A., Cephus, J. Y., Zhang, J., Goleniewska, K., Polosukhin, V. V., Peebles, R. S., & Newcomb, D. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800293 · Cited by 160
“optimal IL-17A production in Th17 cells (19, 26, 45, 46).”
Backgroundvan Baarsen, L. G. M., Lebre, M. C., van der Coelen, D., Aarrass, S., Tang, M. W., Ramwadhdoebé, T. H., Gerlag, D. M., & Tak, P. P. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0426-z · Cited by 168
“Accordingly, several clinical trials targeting the IL-17 pathway in RA [21], psoriasis [22,23], psoriatic arthritis (PsA) [24] and ankylosing spondylitis [25] have been initiated (reviewed in [26]).”
BackgroundImmune and regulatory functions of neutrophils in inflammatory bone loss
Hajishengallis, G., Moutsopoulos, N. M., Hajishengallis, E., & Chavakis, T. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.02.002 · Cited by 145
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schaefer, W., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2019) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 143
Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis
Benedetti, G., & Miossec, P. (2013) · European Journal of Immunology · doi:10.1002/eji.201344184 · Cited by 160
Self-citationNewcomb, D. C., Cephus, J. Y., Boswell, M. G., Fahrenholz, J. M., Langley, E. W., Feldman, A. S., Zhou, W., Dulek, D. E., Goleniewska, K., Woodward, K. B., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.046 · Cited by 158
Self-citationEffects of Interleukin 17 on the cardiovascular system
Robert, M., & Miossec, P. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.009 · Cited by 156
Self-citationTh17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients
Li, D., Cai, W., Gu, R., Zhang, Y., Zhang, H., Tang, K., Xu, P., Katirai, F., Shi, W., Wang, L., et al. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.10.001 · Cited by 153
“Notably, diseases such as multiple sclerosis and psoriasis, which have been thought as Th1-mediated diseases, now are found to be Th17-involved [8,9].”
BackgroundSalehipour, Z., Haghmorad, D., Sankian, M., Rastin, M., Nosratabadi, R., Dallal, M. M. S., Tabasi, N. S., Khazaee, M., Nasiraie, L. R., & Mahmoudi, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.117 · Cited by 147
Cheung, K. L., Zhang, F., Jaganathan, A., Sharma, R., Zhang, Q., Konuma, T., Shen, T., Lee, J.-Y., Ren, C., Chen, C.-H., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.022 · Cited by 137
“…from bacterial and fungal infection (Murphy and Reiner, 2002; Wilson et al., 2009) and are linked to inflammatory disorders, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease (Dong, 2008; Ghoreschi et al., 2011; Littman and Rudensky, 2010; Miossec and Kolls, 2012).”
Periodontitis and cardiometabolic disorders: The role of lipopolysaccharide and endotoxemia
Pussinen, P. J., Kopra, E., Pietiäinen, M., Lehto, M. J., Zarić, S., Paju, S., & Salminen, A. (2022) · Periodontology 2000 · doi:10.1111/prd.12433 · Cited by 164
Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment
Cristiano, C., Volpicelli, F., Lippiello, P., Buono, B., Raucci, F., Piccolo, M., Iqbal, A. J., Irace, C., Miniaci, M. C., Perrone Capano, C., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14586 · Cited by 141
Allergic airway inflammation: key players beyond the Th2 cell pathway
Hirose, K., Iwata, A., Tamachi, T., & Nakajima, H. (2017) · Immunological Reviews · doi:10.1111/imr.12540 · Cited by 146
Luchtman, D. W., Ellwardt, E., Larochelle, C., & Zipp, F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.013 · Cited by 145
“Secukinumab is a fully humanized antibody that neutralizes IL-17A [60].”
BackgroundInfluentialNeutrophil homeostasis and inflammation: novel paradigms from studying periodontitis
Hajishengallis, G., Chavakis, T., Hajishengallis, E., & Lambris, J. D. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3vmr1014-468r · Cited by 155
“A mechanism by which neutrophils can recruit Th17 cells that are implicated in autoimmune and inflammatory conditions, including periodontitis [49–51], involves neutrophil production of CCL2 and CCL20 chemokines.”
BackgroundIL-29 Is Produced by T H 17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis
Wolk, K., Witte, K., Witte, E., Raftery, M., Kokolakis, G., Philipp, S., Schönrich, G., Warszawska, K., Kirsch, S., Prösch, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006245 · Cited by 131
The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
Tsukazaki, H., & Kaito, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176401 · Cited by 152
“In addition to arthritis, IL-17 has been shown to affect bone metabolism by activating the production of matrix metalloproteinases by macrophages and the receptor activator of NF-κB ligand (RANKL) presented by osteoblasts [54,56].”
BackgroundRisk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study
Egeberg, A., Mallbris, L., Gislason, G., Skov, L., & Hansen, P. R. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.350 · Cited by 138
Cheung, K., Lu, G., Sharma, R., Vincek, A. S., Zhang, R., Plotnikov, A. N., Zhang, F., Zhang, Q., Ju, Y., Hu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615601114 · Cited by 139
Neuroinflammation in Alzheimer’s disease: insights from peripheral immune cells
Zhang, Q., Yang, G., Luo, Y., Jiang, L., Chi, H., & Tian, G. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00445-0 · Cited by 155
“Th17 cells are a subtype of helper T lymphocytes known for secreting cytokines such as IL-17 [144].”
BackgroundDeubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells
Rutz, S., Kayagaki, N., Phung, Q. T., Eidenschenk, C., Noubade, R., Wang, X., Lesch, J., Lu, R. O., Newton, K., Huang, O. W., et al. (2014) · Nature · doi:10.1038/nature13979 · Cited by 131
Innate Immune Cell–Produced IL-17 Sustains Inflammation in Bullous Pemphigoid
Jan, S. L., Plée, J., Vallerand, D., Dupont-Deshorgue, A., Delanez, E., Durlach, A., Jackson, P. L., Blalock, J. E., Bernard, P., & Antonicelli, F. D. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.263 · Cited by 139
“Hence, our results relative to BP are in setting with most IL-17 studies, which focused on its ability to drive inflammation in autoimmune disorders including multiple sclerosis, Crohn’s disease, rheumatoid arthritis, psoriasis and ankylosing spondylitis (Miossec and Kolls 2012).”
Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles
Coutant, F., & Miossec, P. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.147 · Cited by 134
Self-citationTh17 cells, γδ T cells and their interplay in EAE and multiple sclerosis
McGinley, A. M., Edwards, S. C., Raverdeau, M., & Mills, K. H. G. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.01.001 · Cited by 147
Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies
Zhao, J., Lu, Q., Liu, Y., Shi, Z., Hu, L., Zeng, Z., Tu, Y., Xiao, Z., & Xu, Q. (2021) · Journal of Immunology Research · doi:10.1155/2021/8816041 · Cited by 143
“IL-17A can exist as a homodimer, or it can pair with IL-17F to form a heterodimer, both of which are present in the colon of hapten-induced colitis mice [83, 84].”
BackgroundBiomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M., & Hamann, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585311 · Cited by 139
Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells
Osta, B., Lavocat, F., Eljaafari, A., & Miossec, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00425 · Cited by 138
Self-citationActivation of Th17 cells in drug naïve, first episode schizophrenia
Ding, M., Song, X., Zhao, J., Gao, J., Li, X., Ge, Y., Wang, X., Harrington, A., Fan, X., & Lv, L. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.001 · Cited by 138
Li, Q., Wang, B., Mu, K., & Zhang, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27180 · Cited by 144
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
Farahani, M., Niknam, Z., Amirabad, L. M., Dashatan, N. A., Koushki, M., Nemati, M., Pouya, F. D., Rezaei–Tavirani, M., Rasmi, Y., & Tayebi, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112420 · Cited by 137
“In addition, immature T helper (Th0) cells can differentiate into Th17 mainly in the presence of IL-6, an inflammatory mediator involved in cytokine release storm in COVID-19 [112].”
Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases
Akhter, S., Tasnim, F. M., Islam, M. N., Rauf, A., Mitra, S., Emran, T. B., Alhumaydhi, F. A., Khalil, A. A., Aljohani, A. S. M., Abdulmonem, W. A., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230904150808 · Cited by 144
Kozakiewicz, L., Chen, Y., Xu, J., Wang, Y., Dunussi‐Joannopoulos, K., Ou, Q., Flynn, J. L., Porcelli, S. A., Jacobs, W. R., & Chan, J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003472 · Cited by 132
“tuberculosis infection [17,31] and in the context of other infectious and autoimmune diseases [15,16,32,33,34].”
BackgroundStrle, K., Stupica, D., Drouin, E. E., Steere, A. C., & Strle, F. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit735 · Cited by 123
“However, aberrant IL23/TH17 responses have been implicated in several autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, lupus, and type 1 diabetes [18–20].”
BackgroundMaekawa, T., Hosur, K., Abe, T., Kantarci, A., Ziogas, A., Wang, B., Van Dyke, T. E., Chavakis, T., & Hajishengallis, G. (2015) · Nature Communications · doi:10.1038/ncomms9272 · Cited by 119
“Indeed, whereas IL-17 upregulates RANKL expression and promotes osteoclastogenesis, IFN γ inhibits RANKL-induced osteoclastogenesis 34,35 .”
Tokarski, J. S., Zupa-Fernandez, A., Tredup, J. A., Pike, K. M., Chang, C. Y., Xie, D., Cheng, L., Pedicord, D. L., Muckelbauer, J. K., Johnson, S. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.619502 · Cited by 129
The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review
Punt, S., Langenhoff, J. M., Putter, H., Fleuren, G. J., Gorter, A., & Jordanova, E. S. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.984547 · Cited by 116
“Antibodies targeting IL-17 and its receptor are now used in clinical trials to treat autoimmune diseases like psoriasis, rheumatoid arthritis, and Crohn’s disease.(6) Since IL-17 can also be produced by innate immune cell types including both lymphoid-derived (e.”
MethodGanor, Y., & Levite, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1167-5 · Cited by 126
RBPJ Controls Development of Pathogenic Th17 Cells by Regulating IL-23 Receptor Expression
Meyer zu Horste, G., Wu, C., Wang, C., Cong, L., Pawlak, M., Lee, Y., Elyaman, W., Xiao, S., Regev, A., & Kuchroo, V. K. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.088 · Cited by 111
“, 2010), in which Th17 cells are important (Miossec and Kolls, 2012).”
BackgroundMolecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis
Woo, Y. R., Cho, D., & Park, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122684 · Cited by 132
Quercetin improves the imbalance of Th1/Th2 cells and Treg/Th17 cells to attenuate allergic rhinitis
Xia, K., Chen, Z., Wang, X., Kang, H., & Hong, S. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2189133 · Cited by 125
“Foxp3, IL-10, and TGF-β are the important regulators for Treg cells, while IL-17 is the regulator for Th17 cells [31,32].”
BackgroundFa’ak, F., Buni, M., Falohun, A., Lu, H., Song, J., Johnson, D. H., Zobniw, C. M., Trinh, V. A., Awiwi, M. O., Tahon, N. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006814 · Cited by 150
Lavoz, C., Matus, Y. S., Orejudo, M., Carpio, J. D., Droguett, A., Egido, J., Mezzano, S., & Ruiz-Ortega, M. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.031 · Cited by 114
Maekawa, T., Abe, T., Hajishengallis, E., Hosur, K. B., DeAngelis, R. A., Ricklin, D., Lambris, J. D., & Hajishengallis, G. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400569 · Cited by 114
“Abbreviations used in this article: ABC, alveolar bone crest; CAL, clinical attachment loss; C5aR, C5a receptor; CEJ, cement–enamel junction; GCF, gingival crevicular fluid; Mob, mobility index; NHP, nonhuman primate; OPG, osteoprotegerin; PPD, probing pocket depth; qPCR, quantitative real-time PCR; RANKL, receptor ac…”
BackgroundResultInfluentialIL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma
Huang, Q., Duan, L., Qian, X., Fan, J., Lv, Z., Zhang, X., Han, J., Wu, F., Guo, M., Hu, G., et al. (2016) · Scientific Reports · doi:10.1038/srep36551 · Cited by 117
The Role of IL-17 Cytokines in Psoriasis
Mosca, M., Hong, J., Hadeler, E., Hakimi, M., Liao, W. J., & Bhutani, T. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240891 · Cited by 127
“IL-17 also promotes procoagulant activity in endothelial cells and upregulates pro-inflammatory effects on macrophages and dendritic cells.(13,21) In addition to this pathway, IL-17 acts synergistically with TNF-α to coregulate psoriasis-related cytokines and keratinocyte genes.”
BackgroundDEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates
Shin, J., Maekawa, T., Abe, T., Hajishengallis, E., Hosur, K., Pyaram, K., Mitroulis, I., Chavakis, T., & Hajishengallis, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5380 · Cited by 112
de Almeida, V. M., Galvão, I., & Vieira, A. T. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0011 · Cited by 120
“They are secreted by either immune or non-immune cells, triggering their effects through binding to IL-17RA-IL-17RE cell receptors (Gaffen 2009; Cua and Tato 2010; Miossec and Kolls 2012; Kim and others 2016).”
Th17 cells and Tregs: unlikely allies
Chen, X., & Oppenheim, J. J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.1213633 · Cited by 123
“Consequently, targeting Th17 cells and Tregs, by up-regulating or down-regulating their respective function, can be considered a promising means of treating autoimmune disorders and tumors [21, 22, 116].”
BackgroundInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
Wasilewska, A., Winiarska, M., Olszewska, M., & Rudnicka, L. (2016) · Advances in Dermatology and Allergology · doi:10.5114/ada.2016.61599 · Cited by 110
“are currently under investigation [31, 32].”
The role of interleukin-17A in the pathogenesis of kidney diseases
Cortvrindt, C., Speeckaert, R., Moerman, A., Delanghe, J., & Speeckaert, M. M. (2017) · Pathology · doi:10.1016/j.pathol.2017.01.003 · Cited by 120
“incorporated into clinical practice for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis.(112) Since IL-17A is important in host defence against bacterial and fungal infections, particularly at mucosal sites, antibodies targeting Th17 may have potential side effects that would adversely affec…”
Martin, D. A., Churchill, M., Flores-Suarez, L. F., Cardiel, M. H., Wallace, D., Martin, R., Phillips, K., Kaine, J. L., Dong, H., Salinger, D., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4347 · Cited by 107
“Aberrant Th17 responses and IL-17 production have been implicated in a variety of human autoimmune diseases, including psoriasis, RA, psoriatic arthritis (PsA) and multiple sclerosis [6,7].”
BackgroundNew Promising Therapeutic Avenues of Curcumin in Brain Diseases
Benameur, T., Giacomucci, G., Panaro, M. A., Ruggiero, M., Trotta, T., Monda, V., Pizzolorusso, I., Lofrumento, D. D., Porro, C., & Messina, G. (2021) · Molecules · doi:10.3390/molecules27010236 · Cited by 118
NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification
Barruet, E., Morales, B. M., Cain, C. J., Ton, A. N., Wentworth, K. L., Chan, T. V., Moody, T. A., Haks, M. C., Ottenhoff, T. H. M., Hellman, J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122958 · Cited by 114
Abnormal immunity of non-survivors with COVID-19: predictors for mortality
Zhao, Y., Nie, H., Hu, K., Wu, X., Zhang, Y., Wang, M. E., Wang, T., Zheng, Z., Li, X., & Zeng, S. (2020) · Infectious Diseases of Poverty · doi:10.1186/s40249-020-00723-1 · Cited by 118
Britton, G. J., Contijoch, E. J., Spindler, M. P., Aggarwala, V., Dogan, B., Bongers, G., Mateo, L. S., Baltus, A. E., Das, A., Gevers, D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922189117 · Cited by 114
“As demonstrated in multiple animal models, increased Th17 cells are associated with susceptibility to inflammatory disease (26).”
BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid
Liu, Y., Li, L., & Xia, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01752 · Cited by 112
Navarro‐Compán, V., Puig, L., Vidal, S., Ramírez, J., Llamas‐Velasco, M., Fernández‐Carballido, C., Almodóvar, R., Pinto, J., Galíndez‐Aguirregoikoa, E., Zarco, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191782 · Cited by 135
Danks, L., & Takayanagi, H. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt049 · Cited by 119
Novel approaches to the management of noneosinophilic asthma
Thomson, N. C. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816632638 · Cited by 110
“Monoclonal inhibitors of IL-17 are in 224 http://tar.sagepub.com clinical development [Miossec and Kolls, 2012].”
BackgroundInteractions between neutrophils and T-helper 17 cells
Fan, X., Shu, P., Wang, Y., Ji, N., & Zhang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279837 · Cited by 116
“Notably, IL-17A regulates respiratory mucus production, and high levels of IL-17A may be linked to severe intestinal and respiratory in fl ammation (62, 63).”
BackgroundA Dormant Microbial Component in the Development of Preeclampsia
Kell, D. B., & Kenny, L. C. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00060 · Cited by 101
Voirin, A.-C., Perek, N., & Roche, F. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146647 · Cited by 99
Th17 and Non-Classic Th1 Cells in Chronic Inflammatory Disorders: Two Sides of the Same Coin
Cosmi, L., Liotta, F., Maggi, E., Romagnani, S., & Annunziato, F. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000363502 · Cited by 124
The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties
Goepfert, A., Lehmann, S., Wirth, E., & Rondeau, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08360-9 · Cited by 107
IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
Shi, Y., Chen, Z., Zhao, Z., Yu, Y., Fan, H., Xu, X., Bu, X., & Gu, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01865 · Cited by 106
Hai, Z., Bo, C., Kang, Y., & Li, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00727 · Cited by 112
“Th17 cells are critical for host protective defense in adaptive immune responses and autoimmune diseases (84).”
BackgroundTargeting of interleukin-17 in the treatment of psoriasis
Lonnberg, Skov, L., & Zachariae, C. O. C. (2014) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s67534 · Cited by 109
“IL-17A, IL-17C, and IL-17F expression has been found to be elevated in psoriatic skin; therefore, targeting of the receptor for all these ligands and not only IL-17A could be more effective in controlling psoriasis, but it might also be associated with an increased risk of infection.(35,40,43) IL-17E has been shown to…”
Papp, K. A., Leonardi, C., Blauvelt, A., Reich, K., Korman, N., Ohtsuki, M., Paul, C. F., Ball, S. G., Cameron, G. S., Erickson, J., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16050 · Cited by 106
Chen, X., Takai, T., Xie, Y., Niyonsaba, F., Okumura, K., & Ogawa, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.024 · Cited by 103
“Interestingly, Th17 cells, IL-17, IL-22, IL-6, and LL-37 are highly accumulated/expressed in skin lesions in patients with psoriasis [1,24].”
BackgroundThe many faces of interleukin-17 in inflammatory skin diseases
Speeckaert, R., Lambert, J., Grine, L., Gele, M. V., Schepper, S. D., & van Geel, N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14703 · Cited by 103
Miossec, P. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000284 · Cited by 96
Self-citationUpdate on regulation and effector functions of Th17 cells
Sandquist, I., & Kolls, J. (2018) · F1000Research · doi:10.12688/f1000research.13020.1 · Cited by 91
Self-citationInflammasome activation and Th17 responses
Deng, J., Yu, X.-Q., & Wang, P.-H. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2018.12.024 · Cited by 93
Khella, C. M., Asgarian, R., Horvath, J. M., Rolauffs, B., & Hart, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041996 · Cited by 106
Targeting the IL-17–TH17 pathway
Bartlett, H. S., & Million, R. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4518 · Cited by 94
Chan, A. J., Alikhan, M. A., Odobasic, D., Gan, P., Khouri, M. B., Steinmetz, O. M., Mansell, A. S., Kitching, A. R., Holdsworth, S. R., & Summers, S. A. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.023 · Cited by 97
Anti-IL17 therapies for psoriasis
Silfvast‐Kaiser, A., Paek, S. Y., & Menter, A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1555235 · Cited by 96
“induces a Th2 response against extracellular organisms [9,10].”
BackgroundLy, K., Smith, M. P., Thibodeaux, Q. G., Reddy, V. D., Liao, W. J., & Bhutani, T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1679625 · Cited by 100
“This inflammatory response functions to activate target tissues against extracellular pathogens and initiate the recruitment of granulocytes to the stimulated site [14,22].”
BackgroundSlowikowski, K., Nguyen, H. N., Noss, E. H., Simmons, D. P., Mizoguchi, F., Watts, G. F. M., Gurish, M. F., Brenner, M. B., & Raychaudhuri, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912702117 · Cited by 89
“However, clinical trials of IL-17A inhibitors with RA patients have shown mixed results (55).”
BackgroundImpact of systemic factors in shaping the periodontal microbiome
Teles, F., Wang, Y., Hajishengallis, G., Hasturk, H., & Marchesan, J. T. (2021) · Periodontology 2000 · doi:10.1111/prd.12356 · Cited by 88
Cui, H., Wang, N., Li, H., Bian, Y., Wen, W., Kong, X., & Wang, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01505-0 · Cited by 103
“Th17 cells secrete several cytokines, including IL-17, IL-21, and IL-23, which contribute to pro-inflammatory responses [5].”
BackgroundEnigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis
Kugyelka, R., Kohl, Z., Olasz, K., Mikecz, K., Rauch, T. A., Glant, T. T., & Boldizsár, F. (2016) · Mediators of Inflammation · doi:10.1155/2016/6145810 · Cited by 102
“A total of 252 RApatients with inadequate responses tomethotrexate were included in a subsequent phase II trial which also failed to find evidence on the clinical efficacy and, therefore, it was concluded that Brodalumab seems to be ineffective in RA (Table 2) [76].”
BackgroundInfluentialCheng, W., van Asten, S. D., Burns, L. A., Evans, H. G., Walter, G. J., Hashim, A., Hughes, F. J., & Taams, L. S. (2016) · European Journal of Immunology · doi:10.1002/eji.201545871 · Cited by 97
T Regulatory and T Helper 17 Cells in Primary Sjögren’s Syndrome: Facts and Perspectives
Alunno, A., Carubbi, F., Bistoni, O., Caterbi, S., Bartoloni, E., Mirabelli, G., Cannarile, F., Cipriani, P., Giacomelli, R., & Gerli, R. (2015) · Mediators of Inflammation · doi:10.1155/2015/243723 · Cited by 95
“Two monoclonal antibodies against IL-17 (the fully human IgG1k secukinumab and the humanized IgG4 ixekizumab) are being investigated in inflammatory arthritides [83] and a clinical trial evaluating secukinumab in dry eye patients is currently ongoing (trial NCT01250171).”
BackgroundSlyepchenko, A., Maes, M., Köhler, C. A., Anderson, G., Quevedo, J., Alves, G. S., Berk, M., Fernandes, B. S., & Carvalho, A. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.002 · Cited by 89
Rosillo, M. Á., Sánchéz‐Hidalgo, M., Sánchez‐Fidalgo, S., Aparicio‐Soto, M., Villegas, I., & Alarcón‐de‐la‐Lastra, C. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0850-0 · Cited by 93
“Importantly, targeting IL-17 has demonstrated therapeutic effects in animal models of inflammatory and autoimmune diseases, including RA [32].”
BackgroundMicroscopic Colitis: What Do We Know About Pathogenesis?
Pisani, L. F., Tontini, G. E., Vecchi, M. L., & Pastorelli, L. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000628 · Cited by 94
“However, inappropriate Th17 responses are involved in the pathogenesis of several immune and inflammatory diseases, such as rheumatoid arthritis, psoriasis, Sjögren syndrome, IBD, multiple sclerosis, and systemic lupus erythemathosus.(36,37) Given the double role of IL-17, this cytokine is a god candidate to be involv…”
BackgroundAbe, T., AlSarhan, M., Benakanakere, M. R., Maekawa, T., Kinane, D. F., Cancro, M. P., Korostoff, J. M., & Hajishengallis, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500496 · Cited by 87
“RANKL is produced by activated lymphocytes and stromal/ osteoblastic cells (46) and is associated with periodontal disease activity in humans (36).”
BackgroundPineda, M. A., Lumb, F., Harnett, M. M., & Harnett, W. (2014) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2014.03.003 · Cited by 88
Laubli, H. P., Koelzer, V. H., Matter, M. S., Herzig, P., Schlienger, B. D., Wiese, M. N., Lardinois, D., Mertz, K. D., & Zippelius, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386362 · Cited by 92
“rammed to IL-17 producing cells (TH17 cells) that might induce or support autoimmune diseases including psoriasis or autoimmune hepatitis.(27)”
BackgroundInterleukin 17A promotes diabetic kidney injury
Ma, J., Li, Y. J., Chen, X., Kwan, T., Chadban, S. J., & Wu, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-38811-4 · Cited by 93
Schaffert, H., Pelz, A., Saxena, A., Losen, M. H., Meisel, A., Thiel, A., & Köhler, S. (2015) · European Journal of Immunology · doi:10.1002/eji.201445064 · Cited by 87
Friedrich, M., Diegelmann, J., Schauber, J., Auernhammer, C. J., & Brand, S. (2014) · Mucosal Immunology · doi:10.1038/mi.2014.124 · Cited by 91
Metadata
- Authors
- Miossec, P., & Kolls, J. K.
- Affiliations
- Lyon 1 Université (FR)
- University of Pittsburgh (US)
- Corresponding author
- Miossec, Pierre
- Kolls, Jay K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 763-776
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2022917731
- Cited by
- 1,414
- References
- 169
- Citations by year
- 2026: 74 · 2025: 104 · 2024: 137 · 2023: 101 · 2022: 121 · 2021: 129 · 2020: 97 · 2019: 91 · 2018: 67 · 2017: 114 · 2016: 100 · 2015: 109 · 2014: 97 · 2013: 72 · 2012: 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Universitaire de France
- Institut Mérieux
- National Heart, Lung, and Blood Institute (R37HL079142)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, Th17 cells, IL-17 inhibitors, IL-23, IL-17 receptor A, psoriasis, rheumatoid arthritis, ankylosing spondylitis, chronic inflammation, autoimmunity, biologic therapy, IL-17A
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Drug Delivery Systems, Interleukin-17, Receptors, Interleukin-17, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.